Werewolf

Werewolf Therapeutics to Present Data on its INDUKINE™ Product Candidates at the Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Wednesday, October 27, 2021
2021 Essex County Council election, Poster, Cancer, Neoplasm, Immunotherapy, Cytokine, Society, Werewolf, IND, Nasdaq, Therapy, GLOBE, SITC, Syngenic, Tumor microenvironment, Pharmaceutical industry, Vaccine, Medical imaging

Title/Abstract number: WTX-613, a conditionally activated IFN INDUKINE molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models.

Key Points: 
  • Title/Abstract number: WTX-613, a conditionally activated IFN INDUKINE molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models.
  • Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.
  • Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment.
  • Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors.

Starlux Games Announces the Launch of Bump Rumble

Retrieved on: 
Thursday, September 16, 2021
Children, Other Retail, Online Retail, Specialty, General Entertainment, Entertainment, Retail, Family, Consumer, Teens, Parenting, MSRP, Movement, SLG, Flag, Werewolf, Toy, Entertainment

Were super excited about the launch of this super silly game we call, A smack for the whole family,' says Judd King, Founder of Starlux Games.

Key Points: 
  • Were super excited about the launch of this super silly game we call, A smack for the whole family,' says Judd King, Founder of Starlux Games.
  • In Bump Rumble, red team battles blue in five ridiculous bouts of bumping, balancing and racing.
  • There are five exciting game options: Bump Race, Bump Battle, Bump Royale, Bumpers Choice, and Bump Relay.
  • About Starlux Games LLC: SLG was formed in 2014 to offer popular, award-winning active play options for youth.

Werewolf Therapeutics Announces Clinical Trial Collaboration with Merck on its WTX-124 INDUKINE™ Program

Retrieved on: 
Wednesday, August 18, 2021
MSD, Company, Terminology, Therapy, Cancer, Werewolf, U.S. Securities and Exchange Commission, GLOBE, SEC, Merck, Nasdaq, Private Securities Litigation Reform Act, Food, Tumor microenvironment, Clinical trial, IND, Safety, Patient, Pembrolizumab, FDA, Toxic epidermal necrolysis, COVID-19, Security (finance), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry

The planned clinical trial will be conducted by Werewolf Therapeutics and is designed to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with KEYTRUDA in patients with solid tumors.

Key Points: 
  • The planned clinical trial will be conducted by Werewolf Therapeutics and is designed to evaluate the safety and preliminary efficacy of WTX-124 as a monotherapy and in combination with KEYTRUDA in patients with solid tumors.
  • The clinical benefit of targeting IL-2 as a treatment for cancer has long been established; however, its utility has been limited by challenging toxicities.
  • Werewolf Therapeutics plans to submit an investigational new drug (IND) application for WTX-124 to the U.S. Food and Drug Administration (FDA) in the first half of 2022.
  • Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the bodys immune system for the treatment of cancer.